Filter
Reset all

Subjects

Content Types

Countries

API

Data access

Data access restrictions

Database access

Database licenses

Data licenses

Data upload

Enhanced publication

Institution responsibility type

Institution type

Keywords

PID systems

Provider types

Quality management

Repository languages

Software

Syndications

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 6 result(s)
<<<!!!<<<The repository is no longer available <<<!!!<<< TOXNET has moved. Most content will continue to be collected and reviewed; selected information is accessible through PubChem, PubMed, and Bookshelf. If you have questions, please contact NLM Customer Support at https://support.nlm.nih.gov/ >>>!!!>>>
Country
Data Download section provides easy access to the ABMI’s data and innovative data products ranging from raw field data, to species habitat associations, to remote sensing and geospatial products, to animal camera trap data, and more.
ChEMBL is a database of bioactive drug-like small molecules, it contains 2-D structures, calculated properties (e.g. logP, Molecular Weight, Lipinski Parameters, etc.) and abstracted bioactivities (e.g. binding constants, pharmacology and ADMET data). The data is abstracted and curated from the primary scientific literature, and cover a significant fraction of the SAR and discovery of modern drugs We attempt to normalise the bioactivities into a uniform set of end-points and units where possible, and also to tag the links between a molecular target and a published assay with a set of varying confidence levels. Additional data on clinical progress of compounds is being integrated into ChEMBL at the current time.
The THEMIS mission is a five-satellite Explorer mission whose primary objective is to understand the onset and macroscale evolution of magnetospheric substorms. The five small satellites were launched together on a Delta II rocket and they carry identical sets of instruments including an electric field instrument (EFI), a flux gate magnetometer (FGM), a search coil magnetometer (SCM), a electro-static analyzer, and solid state telescopes (SST). The mission consists of several phases. In the first phase, the spacecraft will all orbit as a tight cluster in the same orbital plane with apogee at 15.4 Earth radii (RE). In the second phase, also called the Dawn Phase, the satellites will be placed in their orbits and during this time their apogees will be on the dawn side of the magnetosphere. During the third phase (also known as the Tail Science Phase) the apogees will be in the magnetotail. The fourth phase is called the Dusk Phase or Radiation Belt Science Phase, with all apogees on the dusk side. In the fifth and final phase, the apogees will shift to the sunward side (Dayside Science Phase). The satellite data will be combined with observations of the aurora from a network of 20 ground observatories across the North American continent. The THEMIS-B (THEMIS-P1) and THEMIS-C (THEMIS-P2) were repurposed to study the lunar environment in 2009. The spacecraft were renamed ARTEMIS (Acceleration, Reconnection, Turbulence and Electrodynamics of the Moon’s Interaction with the Sun), with the P1 and P2 designations maintained.
SureChemOpen is a free resource for researchers who want to search, view and link to patent chemistry. For end-users with professional search and analysis needs, we offer the fully-featured SureChemPro. For enterprise users, SureChemDirect provides all our patent chemistry via an API or a data feed. The SureChem family of products is built upon the Claims® Global Patent Database, a comprehensive international patent collection provided by IFI Claims®. This state of the art database is normalized and curated to provide unprecedented consistency and quality.